|Bid||85.11 x 900|
|Ask||86.46 x 900|
|Day's range||85.51 - 86.79|
|52-week range||73.12 - 88.91|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||36.31|
|Earnings date||17 Feb 2022|
|Forward dividend & yield||1.12 (1.30%)|
|Ex-dividend date||02 Dec 2021|
|1y target est||97.80|
Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.
Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.
Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.